<DOC>
	<DOCNO>NCT02175212</DOCNO>
	<brief_summary>The present study phase III randomize multicentric trial evaluate potential additional impact effect two year adjuvant androgen deprivation combine neoadjuvant ( 4 month ) high-dose ( 76 Gy ) conformal radiotherapy moderate high-risk prostate cancer patient . Stratification perform prognostic factor participate institution .</brief_summary>
	<brief_title>Clinical Trials Adjuvant Androgen Deprivation Localized Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<criteria>Histological proven adenocarcinoma prostate Stage : cT1c3b N0M0 accord American Joint Committee Cancer ( AJCC ) Tumor Node Metastasis ( TNM ) Prostatic Specific Antigen ( PSA ) &lt; 100 ng/ml Intermediate ( T1T2 Gleason Score [ GS ] 7 and/or PSA 1020 ) High risk ( T3 and/or GS 810 and/or PSA &gt; 20 ) Karnofsky Index ( KI ) performance status â‰¥70 % Written inform consent T4 N1 M1 , Previous surgical treatment ( prostatectomy cryosurgery ) Neoadjuvant hormonal treatment &gt; 3 month . History pelvic radiotherapy ( RT ) Contraindications radiotherapy Concomitant use chemotherapy Serious psychiatric medical condition Current synchronic malignancy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Patients prostate adenocarcinoma</keyword>
</DOC>